Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

Rhea-AI Summary

Cara Therapeutics, Inc. (Nasdaq: CARA) will host a conference call on March 1, 2022, at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results and provide company updates. The call will be accessible via phone or a live audio webcast on their website. Cara is focused on pruritus treatments and has FDA-approved KORSUVA™ (difelikefalin) for moderate-to-severe pruritus associated with chronic kidney disease. The company is also developing an oral version and plans to initiate Phase 3 programs in early 2022.

Positive

• FDA approval of KORSUVA™ for moderate-to-severe pruritus.
• Plans to initiate Phase 3 trials for oral difelikefalin in 2022.

Negative

• None.

STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Tuesday, March 1, 2022, at 4:30 p.m. ET to report fourth quarter and full year 2021 financial results and provide a corporate update.

To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 1891805. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and plans to initiate Phase 3 programs in the first quarter of 2022 for the treatment of pruritus in patients with atopic dermatitis and non-dialysis-dependent chronic kidney disease. Phase 2 trials of oral difelikefalin are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com

FAQ

When will Cara Therapeutics announce its Q4 and full year 2021 financial results?

Cara Therapeutics will announce its Q4 and full year 2021 financial results on March 1, 2022.

What is KORSUVA™ and its significance for Cara Therapeutics?

KORSUVA™ (difelikefalin) is the first FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease.

What are the future plans for Cara Therapeutics regarding oral difelikefalin?

Cara Therapeutics plans to initiate Phase 3 programs for oral difelikefalin in 2022.

How can I access the Cara Therapeutics conference call?

The conference call can be accessed by dialing (855) 445-2816 domestically or (484) 756-4300 internationally, and it will also be available via a live audio webcast on their website.